NeuroSense Therapeutics Ltd. (NRSN) News
Track canonical SquawkNews coverage tagged to NRSN, NeuroSense Therapeutics Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NeuroSense Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 10:30 AM UTC
L
HC Wainwright & Co. maintains Buy rating on NeuroSense Therapeutics, $52 price target
HC Wainwright & Co. maintained their Buy rating on NeuroSense Therapeutics's stock with a price target of $52.00.The price target implies an upside of 648.2% from the Sep 25 close of $6.95.Key takeaways from the analyst
EQUITY | Sep 28, 2026, 10:20 AM UTC
L
NeuroSense Therapeutics 1H Loss/Shr $2.10 >NRSN
NeuroSense Therapeutics 1H Loss/Shr $2.10 >NRSN
NEWS | Sep 25, 2026, 08:31 PM UTC
L
NeuroSense Provides Business Update and Progress for the First Half of 2026
CAMBRIDGE, Mass., Sept. 25, 2026 // -- Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative
NEWS | Sep 25, 2026, 08:30 PM UTC
L
NeuroSense Therapeutics initiated at Buy by HC Wainwright
HC Wainwright & Co. initiated NeuroSense Therapeutics at Buy, per Benzinga ratings actions.
EQUITY | Sep 03, 2026, 10:29 AM UTC
L
NeuroSense Therapeutics Q2'26 EPS seen at (0.20) USD
NeuroSense Therapeutics Ltd. is set to announce Q2'26 results on September 02. The Q2'26 revenue estimate is 0 USD, with EPS anticipated at (0.20) USD.
EARNINGS | Sep 01, 2026, 11:00 AM UTC
L
NeuroSense (NRSN) issues CEO letter to shareholders
NeuroSense (NRSN) has issued a CEO letter to shareholders, according to TradeXchange Newsdesk, with no additional figures or details provided in the alert.
EQUITY | Aug 13, 2026, 01:31 PM UTC
M
NeuroSense Advances Toward December 2026 Filing
NeuroSense completes pre-filing process with Health Canada
EQUITY | Aug 06, 2026, 03:29 PM UTC
L
NRSN Buy, $3 PT – funding remains the gating factor @ Roth
NRSN Buy, $3 PT – funding remains the gating factor @ Roth
EQUITY | Jul 23, 2026, 01:10 PM UTC
L
NRSN Neurosense Therapeutics - expects to file submission to health Canada in coming months
NRSN Neurosense Therapeutics - expects to file submission to health Canada in coming months
EQUITY | Jul 22, 2026, 12:35 PM UTC
H
NRSN Reports Positive Biomarker Findings
NeuroSense reports positive biomarker findings from Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer's disease
EQUITY | Jun 25, 2026, 01:23 PM UTC